tion of incretin-based therapy: Therapeutic potential, patient selec-tion and clinical use. Am J Med 122:S37–S50 8.Holst JJ, Vilsboll T, Deacon CF 2009 The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 297:127–136 9.Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC 1996 Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7–36) amide in pa-tients with NIDDM. Diabetes 45:1524–1530 10.Larsen J, Hylleberg B, Ng K, Damsbo P 2001 Glucagon-like pep- tide-1 infusion must be maintained for 24 h/day to obtain acceptableglycemia in type 2 diabetic patients who are poorly controlled onsulphonylurea treatment. Diabetes Care 24:1416–1421 11.Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG 2008 Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in pa-tients with type 2 diabetes treated for at least 3 years. Curr Med ResOpin 24:275–286